Počet záznamů: 1
Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger
- 1.
SYSNO ASEP 0349341 Druh ASEP J - Článek v odborném periodiku Zařazení RIV J - Článek v odborném periodiku Poddruh J Článek ve WOS Název Bioenergetic pathways in tumor mitochondria as targets for cancer therapy and the importance of the ROS-induced apoptotic trigger Tvůrce(i) Ralph, S.J. (AU)
Rodriguez-Enriquez, S. (MX)
Neužil, Jiří (BTO-N) RID
Moreno-Sanchez, R. (MX)Zdroj.dok. Molecular Aspects of Medicine. - : Elsevier - ISSN 0098-2997
Roč. 31, č. 1 (2010), s. 29-59Poč.str. 31 s. Jazyk dok. eng - angličtina Země vyd. NL - Nizozemsko Klíč. slova Mitocans ; reactive oxygen species ; anti-cancer drugs Vědní obor RIV EB - Genetika a molekulární biologie CEZ AV0Z50520701 - BTO-N (2007-2013) UT WOS 000276729700003 DOI 10.1016/j.mam.2009.12.006 Anotace Mitochondria are emerging as idealized targets for anti-cancer drugs. Although they are inherent to all cells, drugs are being developed that selectively target the mitochondria of malignant cells without adversely affecting normal cells. Such anti-cancer drugs destabilizing mitochondria are referred to as mitocans, classified into several groups according to their mode of action and the location or nature of their specific targets. Many mitocans selectively interfere with the functions of cancer cell mitochondria, causing major disruptions often associated with overloads in ROS production leading to the induction of apoptosis. A common theme emerging is that mitochondrially mediated ROS activation as an apoptosis trigger offers a powerful basis for cancer therapy. Continued research is likely to identify increasing numbers of novel agents that should prove highly effective against a variety of cancers, circumventing tumor resistance to the other more established approaches Pracoviště Biotechnologický ústav Kontakt Monika Kopřivová, Monika.Koprivova@ibt.cas.cz, Tel.: 325 873 700 Rok sběru 2011
Počet záznamů: 1